Prostate cancer that progresses after enzalutamide treatment is poorly responsive to further antiandrogen therapy, and paradoxically, rapid cycling between high and low serum testosterone concentrations (bipolar androgen therapy [BAT]) in this setting might induce tumour responses. We aimed to evaluate BAT in patients with metastatic castration-resistant prostate cancer that progressed after enzalutamide.

中文翻译：

---

恩杂鲁胺进展后转移性去势抵抗性前列腺癌男性的双极雄激素治疗：一项开放标签、2 期、多队列研究。

在恩杂鲁胺治疗后进展的前列腺癌对进一步的抗雄激素治疗反应不佳，而且矛盾的是，在这种情况下，高和低血清睾酮浓度（双极雄激素治疗 [BAT]）之间的快速循环可能会诱导肿瘤反应。我们旨在评估恩杂鲁胺后进展的转移性去势抵抗性前列腺癌患者的 BAT。